Analysis of Adaptive Immunomodulation Before and After Anifrolumab Treatment

Analysis of Adaptive Immunomodulation Before and After Anifrolumab Treatment - BCRANIFRO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049326

Enrollment

Registered

2023-01-11

Start date

2022-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic lupus erythematosus

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: SLE patients who are going to start anifrolumab treatment at the discretion of the treating physician

Exclusion criteria

Exclusion criteria: 1. Patients with other connective tissue diseases or systemic autoimmune diseases (complication with antiphospholipid antibody syndrome controlled by appropriate anticoagulant therapy and connective tissue diseases that do not affect the judgment on the efficacy of anifrolumab are not excluded). 2.Complication with serious life-threatening lung disease. 3.Complication with serious active lupus nephritis or central lupus, for which steroid pulse therapy or cyclophosphamide is indicated. etc.

Design outcomes

Primary

Measure	Time frame
B cell receptor repertoire before and 6 months after treatment with anifrolumab	—

Countries

Japan

Contacts

Public ContactYumi Tsuchida

Graduate School of Medicine, The University of Tokyo Department of Allergy and Rheumatology

yumitsuchida@g.ecc.u-tokyo.ac.jp03-3815-5411

Outcome results